findmyKOL
Clinical trialNCT02628405UnknownPhase 1/PHASE2Interventional

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

SponsorAcademic and Community Cancer Research UnitedEnrollment30Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) and that has not responded to previous treatment (refractory). Drugs used in chemotherapy, such as rituximab, ifosfamide, carboplatin, etoposide, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide with R-ICE may be a better treatment for patients with diffuse large B-cell lymphoma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic in Florida

    Jacksonville, Florida, United States

  • Carle Cancer Center Nci Community Oncology Research Program

    Urbana, Illinois, United States

  • University of Iowa/holden Comprehensive Cancer Center

    Iowa City, Iowa, United States

  • Siouxland Regional Cancer Center

    Sioux City, Iowa, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, United States

  • Coborn Cancer Center at Saint Cloud Hospital

    Saint Cloud, Minnesota, United States

  • Metro Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota, United States

  • Dartmouth Hitchcock Medical Center/dartmouth Cancer Center

    Lebanon, New Hampshire, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, United States

  • State University of New York Upstate Medical University

    Syracuse, New York, United States

  • Rapid City Regional Hospital

    Rapid City, South Dakota, United States

  • Marshfield Medical Center-Marshfield

    Marshfield, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Etoposide →Ifosfamide →Lenalidomide →Rituximab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 May 2016
Primary completion
24 Sept 2021
Completion
20 Dec 2025
Last update posted
1 Jul 2024
Registered enrollment
30
Registry id
NCT02628405
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.